This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

4 Biggest Earnings Releases Next Week

Stocks in this article: PFE ANR F SIRI

NEW YORK ( TheStreet) -- Another week into this fall's earnings season and Wall Street is still moving at full speed. Here is what to watch. PFE Chart PFE data by YCharts

Pfizer (PFE)

Background: Pfizer, a biopharmaceutical company, engages in the discovery, development, manufacture and sale of medicines for people and animals worldwide. Pfizer trades an average of 27 million shares per day with a marketcap of $191 billion.

52-Week Range: $18.15 to $26.09

Book Value: $10.65

Price to Book: 2.4

Pfizer is forecast to record lower third-quarter earnings before the market opens on Oct. 30.

The consensus estimate is currently 53 cents a share, a drop of 9 cents (14.5%) from 62 cents during the equivalent quarter last year. Analysts' estimates this quarter range from 49 cents, to a high of 57 cents per share. The estimates are not pretty, but at least they are fully priced in.

TheStreet's Henry Schwartz writes about Pfizer in HOV, NOK, PFE: A Few Updates .

Seventeen analysts rate Pfizer a buy or strong buy out of 21 analysts. The company has three holds and one total sell ratings. Shares have really appreciated, gaining 30% in the last year, and the average analyst target price for Pfizer is $27.94.

Pfizer is in a strong bull trend. The moving averages are trending higher, and shareholders are making capital gains. I have written about Pfizer in several articles at TheStreet. I like Pfizer for the outsized dividend. Trend followers will hold a long position until a technical break results in a signal to exit.

As mentioned, Pfizer currently pays 88 cents per share in dividends for a yield of 3.5%. The payout percentage is well under 50%, based on this year's estimated earnings of $2.21

Shares moved higher 3.5% in the last month, and I believe the price will remain strong, and shares should be bought on dips. While I don't believe the current health care policies are helping drug makers, Pfizer is positioned to continue paying their healthy dividend.

Short sellers are next to impossible to find. Short interest is so low I only include it to demonstrate the smart money is not betting against this company: 0.8% of the float is short based on the last reported numbers.

PFE Revenue Quarterly Chart PFE Revenue Quarterly data by YCharts

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,082.19 +51.98 0.29%
S&P 500 2,090.09 +8.21 0.39%
NASDAQ 4,796.5520 +23.08 0.48%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs